LifeStance Health Group (LFST) to Release Quarterly Earnings on Wednesday

LifeStance Health Group (NASDAQ:LFST) is anticipated to announce its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect LifeStance Health Group to post earnings of $0.0539 per share and revenue of $378.5140 million for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 8:30 AM ET.

LifeStance Health Group Stock Performance

Shares of NASDAQ:LFST opened at $7.09 on Tuesday. The company has a market capitalization of $2.76 billion, a price-to-earnings ratio of -236.33 and a beta of 1.12. LifeStance Health Group has a 52 week low of $3.74 and a 52 week high of $8.30. The company has a quick ratio of 1.58, a current ratio of 1.58 and a debt-to-equity ratio of 0.18. The firm has a 50 day moving average of $7.11 and a 200 day moving average of $6.15.

Analysts Set New Price Targets

LFST has been the subject of several recent research reports. BTIG Research boosted their price target on LifeStance Health Group from $10.00 to $11.00 and gave the stock a “buy” rating in a research report on Monday, February 2nd. Wall Street Zen upgraded LifeStance Health Group from a “hold” rating to a “buy” rating in a research note on Sunday, February 8th. Zacks Research lowered shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 5th. BMO Capital Markets began coverage on shares of LifeStance Health Group in a research report on Thursday, November 13th. They issued an “outperform” rating and a $8.00 price objective on the stock. Finally, UBS Group boosted their price objective on shares of LifeStance Health Group from $9.00 to $10.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, LifeStance Health Group currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.00.

Insiders Place Their Bets

In related news, insider Ann Varanakis sold 50,000 shares of the company’s stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $6.90, for a total value of $345,000.00. Following the transaction, the insider directly owned 315,610 shares of the company’s stock, valued at $2,177,709. This represents a 13.68% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Robert Bessler sold 119,942 shares of LifeStance Health Group stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $7.04, for a total value of $844,391.68. Following the sale, the director directly owned 1,318,983 shares of the company’s stock, valued at approximately $9,285,640.32. This represents a 8.34% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 270,086 shares of company stock worth $1,891,264 over the last three months. Corporate insiders own 6.60% of the company’s stock.

Hedge Funds Weigh In On LifeStance Health Group

Hedge funds and other institutional investors have recently bought and sold shares of the business. Bayesian Capital Management LP acquired a new stake in LifeStance Health Group during the 2nd quarter valued at approximately $52,000. Cibc World Markets Corp purchased a new position in shares of LifeStance Health Group during the fourth quarter worth $77,000. Qtron Investments LLC purchased a new position in shares of LifeStance Health Group during the fourth quarter worth $83,000. Northwestern Mutual Wealth Management Co. lifted its position in LifeStance Health Group by 569.1% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 12,024 shares of the company’s stock valued at $85,000 after purchasing an additional 10,227 shares during the period. Finally, Orion Porfolio Solutions LLC purchased a new stake in LifeStance Health Group in the fourth quarter valued at $88,000. Institutional investors and hedge funds own 85.50% of the company’s stock.

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.